Mentice Ab · OMXSTO:MNTC
Mentice Ab — Investor Presentation (February 2024)
35 slides from Mentice Ab's investor presentation, Feb 15, 2024
Slide 1: Company IR Presentation
Company IR Presentation Image-guided Interventional Therapies (IGIT) – Global Innovation since 1999 Performance Solutions for Device and Procedural Adoption February 15, 2024 1
Slide 2: Disclaimer
Disclaimer | This information is intended only for the person or entity in the European market to which it is addressed and may contain confidential and/or privileged material. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by pe
Slide 3: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress 6 Financial update & How your investment will support our joint mission 4
Slide 4: Why we do it
This is Mentice Why we do it Mentice solutions are being used around the world to help improve and standardize procedural device efficiency. The pandemic has highlighted the importance of reducing learning on patients. Large variance in mortality rate between hospitals Variance in mortality rates ac
Slide 5: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress 6 Financial update & How your investment will support our joint mission 6
Slide 6: Comparable Simulation Use-Case
This is Mentice Comparable Simulation Use-Case Flight simulation is mandatory Healthcare simulation is not mandatory 7
Slide 7: The clinical disease at the core of our mission
This is Mentice The clinical disease at the core of our mission Image-guided interventional therapies (IGIT): the art of optimizing the body’s blood vessels and internal organs to their intended form and function Endovascular (IGIT) vs. Open Surgery Benefits of Endovascular (IGIT) In comparison to t
Slide 8: Solution Portfolio
This is Mentice Solution Portfolio VR Simulators Physiological flow systems Cloud-based app solutions Ankyras Decision Support VIST® G7 AND G7+ unique Physical anatomical vessel and Mentice® Live, mobile module Provides Physicians and the patent protected haptics with flow models for real device app
Slide 9: Lifecycle of solutions for IGIT
This is Mentice Lifecycle of solutions for IGIT Mentice portfolio is applicable throughout the Product Lifecycle for industry partners DESIGN & PROCEDURE & DEVICE CONTINUOUS USE & DEBRIEF AFTER DEVICE VALIDATION LAUNCH DEVELOPMENT ADOPTION MONITORING INTERVENTION VR Simulators Physiological flow sys
Slide 10: Customers who trust Mentice Solutions
Customers Customers who trust Mentice Solutions Business Areas HEALTH-SYSTEMS IMPROVING PATIENT OUTCOMES THE INDUSTRY SUPPORTING BEST PRACTICE STRATEGIC ALLIANCES THE PATH TO EVERY OR* Healthsystems Medical Device Industry Strategic Alliances Initial acquisition of skills Conceptual design and c
Slide 11: Team collaboration and clinical pathway optimization
Customer use-case Team collaboration and clinical pathway optimization Full Clinical team training on an acute Virtual Patient simulation Complication management training at Sahlgrenska University Hospital, Gothenburg 12
Slide 12: How our MedTech customers benefit from our solutions
Customer Use-case How our MedTech customers benefit from our solutions Recent case example from top device manufacturer and a new pacemaker placement design. Traditional method with traditional theory-based learning = unimpressive and resulting in insecure physicians New device adoption based on:
Slide 13: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress 6 Financial update & How your investment will support our joint mission 14
Slide 14: Mentice at a glance
1999 +60 550+ MENTICE FOUNDED ENGINEERS FOCUSING HOSPITAL CLIENTS PRODUCTS AND DEVELOPMENT 120 2500+ 150+ FULL TIME EQUIVALENT IGIT SIMULATION 13 PAPERS & ARTICLES SYSTEMS SOLD WORLDWIDE SWEDEN 58+ US PATENTS & PATENT MNTC SINGAPORE JAPAN CHINA MENTICE PENDING APPLICATIONS INDIA LOCATIONS IN Listed
Slide 15: Selection of Global Key Opinion Leaders
Clinical Advisors Selection of Global Key Opinion Leaders Providing guidance on product & commercial strategy. Mentice Clinical Director Lars Lönn Copenhagen University Hospital, Rigshospitalet Peripheral Vascular Cardiovascular Neurovascular Andrew Kesselman Estevao Carvalho Jens Flensted Lassen Is
Slide 16: Selection of Global Key Opinion Leaders (KOLs)
Clinical Advisors Selection of Global Key Opinion Leaders (KOLs) Providing guidance on product & commercial strategy. Neurovascular Scientific Advisory Board Mentice Clinical Director Lars Lönn Copenhagen University Hospital, Rigshospitalet Mentice Key Opinion Leaders Peripheral Vascular Cardiovascu
Slide 17: Investors & Advisors
This is Mentice Investors & Advisors Visit https://investor.mentice.com/ for latest updates 18
Slide 18: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress 6 Financial update & How your investment will support our joint mission 19
Slide 19: Strategy
This is Mentice Strategy Current position and key strategic pillars Current position Strategic focus >50% market share in IGIT simulation training market, outperforming competition Initiated the transition from VERTICAL EXPANSION ANNUAL RECURRING ATTACHMENT RATE TO M&A WITHIN IGIT REVENUE PORTFOLIO
Slide 20: Why we do not categorize Mentice as a Medical simulation company
This is Mentice Why we do not categorize Mentice as a Medical simulation company Corporate Strategy: Vertical expansion Horizontal focus on the Medical Simulation Market Gastro Robotic Urology, Turp, Arthroscopy Bronchoscopy Laparoscopi Ultrasound Spine Surgery Ob&Gyn Hysteroscopy Endoscopy Surgery
Slide 21: Expanding vertically in the IGIT market
Expanding vertically in the IGIT market The Vertical Virtual Training IGIT Performance Solutions As example> Electrophysiology Predictive Specialty Area # Simulation As example> Structural Heart Predictive Specialty Area # SAM TAM Simulation Initial SOM Current SOM ANKYRAS $40m $75m $0.5bn $1.7bn Pr
Slide 22: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress & CSR 6 Financial update & How your investment will support our joint mission 23
Slide 23: Strategical progress incl. acquired assets
This is Mentice Strategical progress incl. acquired assets From general medical simulation to market leader in the endovascular field with increase from <30% market share to current 55-60% market share Endovascular Xitact Product Change of MSC IPO Vascular Ankyras BioModex simulation (acquisition) A
Slide 24: Mentice CSR initiative – RAD-AID International
This is Mentice Mentice CSR initiative – RAD-AID International Providing simulation solutions and services to RAD-AIDs global program 1st Year IR Fellow at the University of Nairobi 2nd Year IR Fellow at the University of Nairobi “Our catheter and wire navigation skills have really improved since th
Slide 25: Agenda
Agenda 1 Introduction & the challenges we help solve 2 The offering and our customers 3 The company and owners 4 Strategy 5 Progress 6 Financial update & How your investment will support our joint mission 28
Slide 26: Highlights: FY 2023
Highlights: FY 2023 (Financial & Business Highlights) Company in brief Market in brief • Mentice AB (“Mentice” or the “Company”) is a global leading provider of • Large opportunity within the rapidly growing interventional field with performance and training solutions for Image-guided Interventional
Slide 27: Financial Overview
Financial Overview Comments Financial development 2014-2023 SEKm • Mentice has been growing at a high pace Sales CAGR: +14.1% during the last 10 years with a sales CAGR of 300 +14.1% during 2014-2023, totalling SEK 273.6m in 2023 250 25% 200 • Mentice has an EBIT margin at -0.2% in 2023 150 15% but
Slide 28: Order Intake
Order Intake Business Area | Q4-2023 Positive trend overall driven by industry • Positive growth trend for the last 4 years • Strong overall order intake for Q4 2023. Full year order intake +20.6%. • Medical Device Industry up with 52.5% for the quarter mainly driven by the US ORDER INTAKE PER SEGME
Slide 29: Net sales
Net sales Regions and segments | Q4-2023 Different profile Net sales at 70.4 MSEK – growth 2.5% for fourth quarter NET SALES PER QUARTER, TSEK • Americas region presenting strong growth year over year, related to medical device industry. Fourth quarter a consequence of overall strong performance q1-
Slide 30: Order Book and recurring revenue
Order Book and recurring revenue ORDER BOOK PER QUARTER Q4-2023 Orderbook at 156.3 (126.0) MSEK – growth 24% • Systems and SW for customer capex, including rental and accessories/spare parts 60.5 MSEK • Development 10.0 MSEK • Software subscription, including Ankyras 45.8 MSEK, whereof 17.4 MSEK in
Slide 31: Financial summary
Financial summary FY (Jan – Dec) 2023 Net sales • 273.6 (218.0) MSEK for the full year giving a 25.5 % growth for the full year with 19.4 % organically Gross margin • Unchanged high gross margin compared with last year: 85.3 (85.4) % EBITDA • Positive EBITDA result for the fifth quarter in a row and
Slide 32: Highlights: Q4-2023
Highlights: Q4-2023 Financial & Business Highlights Order intake of Larger delta between 103.9 net sales and orders Positive EBITDA Net income for the ( 90.3) MSEK, compared to normal 2.3 (11.5) MSEK period +15% yoy growth, first (due to late incoming 3,2 % in margin -2.8 (2.1) MSEK. quarter ever ab
Slide 33: FY Highlights (Jan- Dec 2023)
FY Highlights (Jan- Dec 2023) Financial & Business Highlights Net Sales Order book EBITDA Improved operational 273.6 (218.0) MSEK, MSEK 152.4 (126.0) 24.2 (-3.9) MSEK at cashflow + 25.5% yoy growth whereof 110.0 MSEK 8.8% margin 38.7 (14.9) MSEK scheduled for 2024 The Americas region Order intake of
Slide 34: Why Mentice?
Why Mentice? 1 Global leader in advanced image guided interventional therapies and training solutions 2 Proven business model with strong operational leverage and rapid growth 3 Top-tier client base and strategic partnerships with Philips and Siemens Healthineers 4 Large opportunity connected to the
Slide 35: Thank You!
== mentice Thank You! -mentice linkedin.com/company/mentice © mtercorn/mentice @ tecevooecom/mentice instagrem.com/menticeds foutube.com/user/Mentice info@mentice com